Compare iShares Core US Aggregate Bond ETF (AGG) vs GSK plc (GSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares Core US Aggregate Bond ETF vs GSK plc — how do they compare? iShares Core US Aggregate Bond ETF trades at $98.05, while GSK plc trades at $52.63 (market cap $105.91B). The key difference: GSK plc pays a 3.38% dividend while iShares Core US Aggregate Bond ETF pays none, and GSK plc is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AGG | GSK | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $101.40 | $61.18 |
52-Week Low | $97.63 | $36.20 |
Market Cap | — | $105.91B |
Enterprise Value | — | $126.53B |
Dividend Yield | — | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGG trades at $98.65, up 0.04% on the day, with technical indicators showing a bearish trend from moving averages but a neutral signal from oscillators. The stock faces resistance at $99 and support at $98. Recent corporate actions include scheduled dividends for May and June 2026. Financial ratios are unavailable in the provided data, limiting fundamental analysis.
The outlook remains cautious due to the bearish technical bias and lack of current financial metrics. Key risks include market volatility and interest rate uncertainty. Investors should await updated earnings reports for a clearer fundamental picture before considering positions.
GSK trades at $53.32, down 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with $1.24 EPS, and maintains robust profitability with a 17.78% net income margin. Recent FDA approval for Utebzi and the $10.6 billion acquisition of Nuvalent highlight strategic expansion in oncology and anti-infectives.
Outlook remains positive with 7-9% EPS growth guidance for 2026, though risks include integration of large acquisitions and patent cliffs. Analyst consensus is mixed with 31% buy ratings, but solid fundamentals and recent approvals support a constructive view for long-term investors amid sector competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core US Aggregate Bond ETF
AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.
Read more on AGG →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
